This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Sally Wang Liang
Venture Partner at Viva Bioinnovator

Profile

Sally Wang Liang JD MPH is a Venture Partner at Viva Bioinnovator (VBI), a life sciences corporate venture with 90 portfolio companies globally, most of which are therapeutics companies based in the US. She is a Board Member of Deka, novel cytokine company co-invested by Bayer Leaps, FuseBio, an antibody immune cell engager company, and IpiNovyx, immunoproteasome inhibitors focused biotech co-invested by Lilly, Board Observer for Phenomic AI, AcuraStem and Riparian, and Shareholder Representative for LucyTx, i2o and GenHouse.

She is also SVP of Business Development, Head of the Global Business Unit at PepLib, a peptide discovery and therapeutics company with a novel screening platform. She is actively involved in the biotech ecosystem: serving on the Scientific Advisory Board of New Equilibrium Biosciences, an AI drug discovery company invested by RA Capital, an investor and advisor of AI Proteins, as Expert-in-Residence and President’s Innovation Challenge Judge at the Harvard iLab, and mentor with MassBIO and Activate-Nucleate.

She comes to VBI as a life sciences business executive and a multidisciplinary IP & Regulatory lawyer with 15+ years of healthcare industry experience. Previously, she was Entrepreneur-in-Residence and Acting VP of Investments and General Counsel at Orange Grove Bio, involved in in-licensing promising university technology into NewCo. She has substantial operating, business development, and fundraising experience as a serial entrepreneur in digital health: as the CEO and Co-founder of an international telemedicine company, where she built a patient network of 25M covered lives through partnerships, and as Chief Strategy Officer and EVP of IP and Regulatory of a leading digital therapeutics company. As a lawyer, she practiced pharmaceutical patent litigation and IP licensing at the premier intellectual property firm and clerked for a federal judge. She was also involved in life sciences policy making on the national level at the Food and Drug Administration Office of Policy and the US Senate Health Education Labor Pension Committee Health Office. She began her career as a management consultant at Clarion Healthcare, advising many of the world’s largest pharmaceutical companies and top biotech firms on business strategy. Sally received a A.B. in Biology from Harvard College, a J.D. from Harvard Law School, and a M.P.H from Harvard T.H. Chan School of Public Health.


Agenda Sessions

  • The R&D and Clinical Partnership Playbook

    1:30pm